LIFE aTyr Pharma

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma to Present at Upcoming Investor Conferences

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2024.

Details of the conferences appear below:

Conference: RBC Capital Markets Global Healthcare Conference

Date: Wednesday, May 15, 2024

Time: 8:00am EDT

Location: New York, NY

Format: Fireside Chat

Conference: Piper Sandler Virtual Lung Investor Day

Date: Thursday, May 23, 2024

Time: 12:45pm EDT

Location: Virtual

Format: Fireside Chat

Conference: Jefferies Global Healthcare Conference

Date: Wednesday, June 5, 2024

Time: 4:30pm EDT

Location: New York, NY

Format: Corporate Presentation

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences. A webcast of the RBC and Jefferies events will be available on the Investor’s section of the company’s website at . Following the events, a replay of the RBC and Jefferies presentations will be available on the aTyr website for at least 90 days. For more information, contact .

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit .

Contact: 
Ashlee Dunston 
Director, Investor Relations and Public Affairs              
 
                                   



EN
06/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on aTyr Pharma

Atyr Pharma Inc: 3 directors

Three Directors at Atyr Pharma Inc bought 75,000 shares at between 1.750USD and 1.807USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...

 PRESS RELEASE

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to...

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR” Ticker symbol change to take effect on Wednesday, June 5, 2024 SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will be changing its ticker symbol from “LIFE” to “ATYR.” Effective at the market open on June 5, 2024, the Company’s common stock will trade on the Nasdaq Cap...

 PRESS RELEASE

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635...

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 9,400 shares of aTyr’s common stock, each with an exercise price of $1.86 per share, which is equal t...

 PRESS RELEASE

aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Ac...

aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference Findings further demonstrate that NRP2 is an important new immune target in ILD and that efzofitimod modulates myeloid cells to confer anti-inflammatory benefit SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will...

 PRESS RELEASE

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in P...

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that an inde...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch